Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.044
- Book/Share 16.3757
- PB 1.4941
- Debt/Equity 0.665
- CurrentRatio 1.2822
- ROIC 0.1065
- MktCap 138674407193.0
- FreeCF/Share 1.8252
- PFCF 13.3649
- PE 14.1184
- Debt/Assets 0.2957
- DivYield 0.0705
- ROE 0.1091
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Johnson Fistel Investigates Fairness of Proposed Sale of Metsera
Published: November 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE).
Read More
5 Highest Yielding Dividend Stocks in the S&P 500
Published: November 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and fastest-moving giants.
Read More
Pfizer to acquire Metsera after winning bidding contest against Novo Nordisk
Published: November 10, 2025 by: Proactive Investors
Sentiment: Positive
Metsera (NASDAQ:MTSR) announced that it has entered into an amended merger agreement with Pfizer Inc (NYSE:PFE, ETR:PFE), under which Pfizer will acquire the biotech company for up to $86.25 per share, valuing it at about $10 billion. The offer consists of $65.60 per share in cash and a contingent value right (CVR) for additional payments of up to $20.65 per share based on clinical and regulatory milestones.
Read More
Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.
Read More
Pfizer to buy Metsera in deal worth up to $10 billion
Published: November 10, 2025 by: CNBC Television
Sentiment: Positive
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.
Read More
Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs
Published: November 10, 2025 by: CNBC Television
Sentiment: Positive
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company's up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer's strategy for clinical development and manufacturing.
Read More
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.
Read More
Pfizer: The Storm Has Passed -- Tailwinds Ahead
Published: November 06, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer Inc. remains a Strong Buy with a $33 price target, implying 33% upside over 12-18 months, driven by undervaluation and sector tailwinds. Despite Fiscal Q3 2025 revenue and EPS declines, PFE's future outlook is improving, with new product launches and acquisitions expected to offset losses of exclusivity. PFE's robust dividend yield near 7%, shareholder-friendly capital allocation, and potential Metsera acquisition offer downside protection and growth catalysts.
Read More
What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?
Published: November 06, 2025 by: Reuters
Sentiment: Positive
Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment their pipeline in the booming weight-loss drug market.
Read More
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal
Published: November 06, 2025 by: Benzinga
Sentiment: Neutral
The Delaware Chancery Court denied Pfizer Inc.'s (NYSE:PFE) request for a temporary restraining order to prevent Metsera, Inc. (NASDAQ:MTSR) from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk A/S (NYSE:NVO).
Read More
No Brainer Dividend Stocks To Buy Now
Published: November 06, 2025 by: 24/7 Wall Street
Sentiment: Positive
You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating cash income from their portfolio, but if you handle the income well, you can generate a higher total return through dividend reinvestment while boosting the long-term capital appreciation potential.
Read More
Pfizer says it removed some conditions from its Metsera bid
Published: November 05, 2025 by: Reuters
Sentiment: Neutral
Pfizer has removed some conditions in its bid for Metsera as it tries to overcome a rival $10 billion bid by Novo Nordisk for the obesity drug developer, the U.S. drug giant said in a letter to a Delaware judge on Wednesday.
Read More
Pfizer: Market Still Pricing It At Crisis Valuations
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. remains materially undervalued despite recent volatility, with its recovery momentum challenged by the ongoing Metsera bidding war. PFE's more stable guidance and robust pipeline offer multiple growth pathways, even if the Metsera acquisition turns out to be unsuccessful. The GLP-1 market's increasing competition and pricing pressures may weigh on PFE sentiment, but strong free cash flows and appealing dividend yield support a bullish view.
Read More
Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera
Published: November 05, 2025 by: CNBC
Sentiment: Positive
Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
Read More
Pfizer Inc. (PFE) Q3 2025 Earnings Call Transcript
Published: November 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. ( PFE ) Q3 2025 Earnings Call November 4, 2025 10:00 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman of the Board & CEO David Denton - Executive VP & CFO Aamir Malik Andrew Baum - Chief Strategy & Innovation Officer, Executive VP Chris Boshoff - Chief Scientific Officer and President of Research & Development Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Courtney …
Read More
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera
Published: November 04, 2025 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) has outbid Pfizer Inc (NYSE:PFE, ETR:PFE) in a heated contest for obesity-focused biotech Metsera (NASDAQ:MTSR), with the Danish drugmaker's revised offer valuing the company at roughly $10 billion, compared with Pfizer's $8.1 billion proposal. Metsera's board on Tuesday declared Novo Nordisk's amended bid “superior,” setting the stage for a potential acquisition that could reshape the obesity treatment landscape.
Read More
Pfizer and Novo Nordisk both raise bids for Metsera
Published: November 04, 2025 by: CNBC Television
Sentiment: Positive
CNBC's David Faber breaks down the latest details about a bidding war between Pfizer and Novo Nordisk for Metsera.
Read More
Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer posts Q3 earnings beat and raises EPS guidance, but weaker COVID product sales weigh on overall revenue momentum.
Read More
Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo
Published: November 04, 2025 by: Reuters
Sentiment: Neutral
A Delaware judge said on Tuesday she did not see in a preliminary evaluation the need to involve the court in the bidding war for Metsera between Pfizer and Novo Nordisk, but did schedule another hearing for 3:15 pm ET on Wednesday to review the process.
Read More
Pfizer reports strong Q3 earnings, raises full-year profit guidance
Published: November 04, 2025 by: Proactive Investors
Sentiment: Positive
Pfizer Inc (NYSE:PFE, ETR:PFE) reported third quarter financial results that topped Wall Street expectations despite a year-over-year drop in earnings and sales, while raising its full-year profit guidance. The company reported Q3 revenue of $16.7 billion, slightly above analyst estimates of $16.55 billion, representing a 7% decline compared with the same period last year.
Read More
Here's What Key Metrics Tell Us About Pfizer (PFE) Q3 Earnings
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Metsera said it received a revised acquisition offer from Novo Nordisk that it called superior to Pfizer's bid
Published: November 04, 2025 by: WSJ
Sentiment: Positive
The new offer constitutes a superior company proposal to Pfizer's bid, Metsera said.
Read More
Pfizer's Q3 Earnings Beat on Top and Bottom Lines
Published: November 04, 2025 by: 24/7 Wall Street
Sentiment: Positive
Pfizer (NYSE: PFE) beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 consensus and revenue of $16.65 billion versus $16.50 billion expected.
Read More
Pfizer's revenue falls as COVID sales and vaccine recommendations continue to fade
Published: November 04, 2025 by: Market Watch
Sentiment: Negative
The full-year outlook was lifted, but the stock lost ground.
Read More
Pfizer's Q3: Stagnation Continues
Published: November 04, 2025 by: Seeking Alpha
Sentiment: Negative
Pfizer reported another quarter of stagnation, with Q3 2025 revenue and EPS both declining year-over-year despite beating consensus estimates. PFE's revenue mix remains weak, with Primary Care sales dropping 15.6% and only Oncology showing growth ahead of inflation; management guidance remains largely unchanged. The forward P/E ratio is expected to stagnate, and low valuation multiples reflect poor growth prospects, making sector comparisons misleading.
Read More
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up
Published: November 04, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk and Pfizer have revised their bids for Metsera , the obesity drug developer said on Tuesday.
Read More
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
Published: November 03, 2025 by: CNBC
Sentiment: Negative
Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit escalates a heated standoff between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the blockbuster weight loss drug market.
Read More
Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera
Published: November 03, 2025 by: WSJ
Sentiment: Negative
Lawsuit says the proposed merger of the weight-loss drugmakers could kill off a smaller competitor.
Read More
Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000